ArticleGut microbes2010
In-depth genetic analysis of Clostridium difficile PCR-ribotype 027 strains reveals high genome fluidity including point mutations and inversions.
Article in Gut microbes, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed.
- Comment on the effectiveness of sodium hypochlorite againstMicrobiology (Reading, England) · 2024Article
- Coordinated modulation of multiple processes through phase variation of a c-di-GMP phosphodiesterase in Clostridioides difficile.PLoS pathogens · 2022Article
- Article
- Review
- Higher genome variability within metabolism genes associates with recurrent Clostridium difficile infection.BMC microbiology · 2021Article
- Transition From PCR-Ribotyping to Whole Genome Sequencing Based Typing ofFrontiers in cellular and infection microbiology · 2021Article
- Rho factor mediates flagellum and toxin phase variation and impacts virulence in Clostridioides difficile.PLoS pathogens · 2020Article
- Genomics of the Pathogenic Clostridia.Microbiology spectrum · 2019Review
- Genome-wide detection of conservative site-specific recombination in bacteria.PLoS genetics · 2018Article
- Phase variation of Clostridium difficile virulence factors.Gut microbes · 2018Review
- A genetic switch controls the production of flagella and toxins in Clostridium difficile.PLoS genetics · 2017Article
- The First Two Clostridium difficile Ribotype 027/ST1 Isolates Identified in Beijing, China-an Emerging Problem or a Neglected Threat?Scientific reports · 2016Article
- Article
- Diversity and Evolution in the Genome of Clostridium difficile.Clinical microbiology reviews · 2015Review
- The flagellin FliC of Clostridium difficile is responsible for pleiotropic gene regulation during in vivo infection.PloS one · 2014Article
- Culture-independence for surveillance and epidemiology.Pathogens (Basel, Switzerland) · 2013Article
- Article
- Critical role for MyD88-mediated neutrophil recruitment during Clostridium difficile colitis.Infection and immunity · 2012Article
- Bacterial epidemiology and biology--lessons from genome sequencing.Genome biology · 2011Review
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
Previously, we demonstrated that the recently evolved PCR-ribotype 027 hypervirulent Clostridium difficile strain (R20291) has acquired five genetic regions compared to the historic 027 counterpart strain (CD196), that may in part explain phenotypic traits relating to survival, antimicrobial resistance and virulence. Closer scrutiny of the three genome sequences reveals that, in addition to gene gain/loss, point mutations and inversions appear to have accumulated. Inversions are located upstream of potential coding sequences and could affect expression of these. C. difficile has a highly fluid genome with multiple mechanisms to modify its genetic content and is continuing to evolve in our hospitals influenced by environmental changes and human activity.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.